1. FDA(2000).Guidance for industry waiver ofin vivobioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system.https://www.fda.gov/media/70963/download(accessed January 2021).
2. ]FDA(2019).Title 21 – food and drugs Part 320 – bioavailability and bioequivalence requirements.https://www.govinfo.gov/content/pkg/CFR‐2019‐title21‐vol5/xml/CFR‐2019‐title21‐vol5‐part320.xml(accessed January 2021).
3. EMA(2010).Committee for Medicinal Products for Human Use (CHMP) Guideline on the Investigation of Bioequivalencehttps://www.ema.europa.eu/en/documents/scientific‐guideline/guideline‐investigation‐bioequivalence‐rev1_en.pdf(accessed January 2021).
4. ICH(2020).ICH M9 guideline on biopharmaceutics classification system‐based biowaivers.https://www.ema.europa.eu/en/documents/scientific‐guideline/ich‐m9‐biopharmaceutics‐classification‐system‐based‐biowaivers‐step‐5_en.pdf(accessed January 2021).
5. Food and Drug Administration Centre for Drug Evaluation and Research (CDER) US Department of Health and Human Services(2003).Bioavailability and bioequivalence studies for orally administered drug products—general considerations.https://www.fda.gov/files/drugs/published/Guidance‐for‐Industry‐Bioavailability‐and‐Bioequivalence‐Studies‐for‐Orally‐Administered‐Drug‐Products‐‐‐General‐Considerations.PDF(accessed August 2021)